Advertisement

Clinical Journal of Gastroenterology

, Volume 11, Issue 6, pp 449–456 | Cite as

The evidence for fungus in Crohn’s disease pathogenesis

  • Jun Miyoshi
  • Mark Anthony Sofia
  • Joseph Francis Pierre
Clinical Review

Abstract

Current evidence suggests the etiology of inflammatory bowel diseases (IBD) involves the confluence of host genetic, environmental, and microbial factors that lead to chronic, and often refractory, disease in susceptible individuals. The involvement of microbial triggers in IBD, including Crohn’s disease (CD), is increasingly evident with supporting data provided with advancements in metagenomic sequencing that have identified perturbations in microbial structure and function—broadly termed dysbiosis—in CD patients compared with healthy subjects. This concept is supported by the finding germ-free animals with CD genetic susceptibility fail to develop disease; demonstrating microorganisms are necessary but not sufficient for CD. The vast majority of CD microbiome research has focused on the complex bacterial communities and microbiome dysbiosis in the gut with 16S metagenomic sequencing. However, emerging data capturing eukaryotes suggest fungal opportunistic pathogens are also associated with IBD pathogenesis and chronicity. This hypothesis is further supported by historical observations that CD patient populations display elevated antibodies against fungal targets, even evident before disease diagnosis. This review discusses the current findings in the field, followed by historical and metagenomic evidence for fungal pathogens in the development and recurrence of CD in adult and pediatric populations.

Keywords

Inflammatory bowel diseases Microbiome Mycobiome Fungal pathogens Crohn’s disease 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare no conflicts of interest.

References

  1. 1.
    Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2018;390:2769–78.CrossRefGoogle Scholar
  2. 2.
    Mesbah-Uddin M, Elango R, Banaganapalli B, et al. In-silico analysis of inflammatory bowel disease (IBD) GWAS loci to novel connections. PLoS One. 2015;10:e0119420.CrossRefGoogle Scholar
  3. 3.
    Jostins L, Ripke S, Weersma RK, et al. Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491:119–24.CrossRefGoogle Scholar
  4. 4.
    Mukherjee PK, Sendid B, Hoarau G, et al. Mycobiota in gastrointestinal diseases. Nat Rev Gastroenterol Hepatol. 2015;12:77–87.CrossRefGoogle Scholar
  5. 5.
    Scharl M, Rogler G. Microbial sensing by the intestinal epithelium in the pathogenesis of inflammatory bowel disease. Int J Inflam. 2010; 2010:671258.CrossRefGoogle Scholar
  6. 6.
    Ward MA, Pierre JF, Leal RF, et al. Insights into the pathogenesis of ulcerative colitis from a murine model of stasis-induced dysbiosis, colonic metaplasia, and genetic susceptibility. Am J Physiol Gastrointest Liver Physiol. 2016;310:G973–88.CrossRefGoogle Scholar
  7. 7.
    Goodwin S, McPherson JD, McCombie WR. Coming of age: ten years of next-generation sequencing technologies. Nat Rev Genet. 2016;17:333–51.CrossRefGoogle Scholar
  8. 8.
    Caporaso JG, Kuczynski J, Stombaugh J, et al. QIIME allows analysis of high-throughput community sequencing data. Nat Methods. 2010;7:335–6.CrossRefGoogle Scholar
  9. 9.
    Schloss PD, Westcott SL, Ryabin T, et al. Introducing mothur: open-source, platform-independent, community-supported software for describing and comparing microbial communities. Appl Environ Microbiol. 2009;75:7537–41.CrossRefGoogle Scholar
  10. 10.
    Lee CK, Herbold CW, Polson SW, et al. Groundtruthing next-gen sequencing for microbial ecology-biases and errors in community structure estimates from PCR amplicon pyrosequencing. PLoS One. 2012;7:e44224.CrossRefGoogle Scholar
  11. 11.
    Eren AM, Morrison HG, Lescault PJ, et al. Minimum entropy decomposition: unsupervised oligotyping for sensitive partitioning of high-throughput marker gene sequences. ISME J. 2015;9:968–79.CrossRefGoogle Scholar
  12. 12.
    Carding S, Verbeke K, Vipond DT, et al. Dysbiosis of the gut microbiota in disease. Microb Ecol Health Dis. 2015;26:26191.PubMedGoogle Scholar
  13. 13.
    Pierre JF, Barlow-Anacker AJ, Erickson CS, et al. Intestinal dysbiosis and bacterial enteroinvasion in a murine model of Hirschsprung’s disease. J Pediatr Surg. 2014;49:1242–51.CrossRefGoogle Scholar
  14. 14.
    Matsuoka K, Kanai T. The gut microbiota and inflammatory bowel disease. Semin Immunopathol. 2015;37:47–55.CrossRefGoogle Scholar
  15. 15.
    Qin J, Li R, Raes J, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 2010;464:59–65.CrossRefGoogle Scholar
  16. 16.
    Willing BP, Dicksved J, Halfvarson J, et al. A pyrosequencing study in twins shows that gastrointestinal microbial profiles vary with inflammatory bowel disease phenotypes. Gastroenterology. 2010;139:1844–54.CrossRefGoogle Scholar
  17. 17.
    Martinez C, Antolin M, Santos J, et al. Unstable composition of the fecal microbiota in ulcerative colitis during clinical remission. Am J Gastroenterol. 2008;103:643–8.CrossRefGoogle Scholar
  18. 18.
    Andrews CN, Griffiths TA, Kaufman J, et al. Mesalazine (5-aminosalicylic acid) alters faecal bacterial profiles, but not mucosal proteolytic activity in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2011;34:374–83.CrossRefGoogle Scholar
  19. 19.
    Andoh A, Imaeda H, Aomatsu T, et al. Comparison of the fecal microbiota profiles between ulcerative colitis and Crohn’s disease using terminal restriction fragment length polymorphism analysis. J Gastroenterol. 2011;46:479–86.CrossRefGoogle Scholar
  20. 20.
    Takaishi H, Matsuki T, Nakazawa A, et al. Imbalance in intestinal microflora constitution could be involved in the pathogenesis of inflammatory bowel disease. Int J Med Microbiol. 2008;298:463–72.CrossRefGoogle Scholar
  21. 21.
    Hoffmann C, Dollive S, Grunberg S, et al. Archaea and fungi of the human gut microbiome: correlations with diet and bacterial residents. PLoS One. 2013;8:e66019.CrossRefGoogle Scholar
  22. 22.
    Liguori G, Lamas B, Richard ML, et al. Fungal Dysbiosis in Mucosa-associated Microbiota of Crohn’s Disease Patients. J Crohns Colitis. 2016;10:296–305.CrossRefGoogle Scholar
  23. 23.
    Li Q, Wang C, Tang C. at al. Dysbiosis of gut fungal microbiota is associated with mucosal inflammation in Crohn’s disease. J Clin Gastroenterol. 2014;48:513–23.PubMedPubMedCentralGoogle Scholar
  24. 24.
    Richard ML, Lamas B, Liguori G. at al. Gut fungal microbiota: the Yin and Yang of inflammatory bowel disease. Inflamm Bowel Dis. 2015;21:656–65.CrossRefGoogle Scholar
  25. 25.
    Sokol H, Leducq V, Aschard H, et al. Fungal microbiota dysbiosis in IBD. Gut. 2017;66:1039–48.CrossRefGoogle Scholar
  26. 26.
    Bliss JM, Basavegowda KP, Watson WJ, et al. Vertical and horizontal transmission of Candida albicans in very low birth weight infants using DNA fingerprinting techniques. Pediatr Infect Dis J. 2008;27:231–5.CrossRefGoogle Scholar
  27. 27.
    Suhr MJ, Hallen-Adams HE. The human gut mycobiome: pitfalls and potentials – a mycologist’s perspective. Mycologia. 2015;107:1057–73.CrossRefGoogle Scholar
  28. 28.
    David LA, Maurice CF, Carmody RN, et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature. 2014;505:559–63.CrossRefGoogle Scholar
  29. 29.
    Carvalho A, Giovannini G, De Luca A, et al. Dectin-1 isoforms contribute to distinct Th1/Th17 cell activation in mucosal candidiasis. Cell Mol Immunol. 2012;9:276–86.CrossRefGoogle Scholar
  30. 30.
    Ceng SC, van de Veerdonk FL, Lenardon M, et al. The dectin-1/inflammasome pathway is responsible for the introduction of protective T-helper 17 response that discriminate between yeasts and hyphae of Candida albicans. J Leukoc Biol. 2011;90:357–66.CrossRefGoogle Scholar
  31. 31.
    Gringhuis SI, Kaptein TM, Wevers BA, et al. Dectin-1 is an extracellular pathogen sensor for the induction and processing of IL-1β via a noncanonical caspase-8 inflammasome. Nat Immunol. 2012;13:246–54.CrossRefGoogle Scholar
  32. 32.
    LeibundGut-Landmann S, Gross O, Robinson MJ, et al. Syk- and CARD9-dependent coupling of innate immunity to the induction of T helper cells that produce interleukin 17. Nat Immunol. 2007;8:630–8.CrossRefGoogle Scholar
  33. 33.
    Conti HR, Shen F, Nayyar N, et al. Th17 cells and IL-17 receptor signaling are essential for mucosal host defense against oral candidiasis. J Exp Med. 2009;206:299–311.CrossRefGoogle Scholar
  34. 34.
    Beaudoin M, Goyette P, Boucher G, et al. Deep resequencing of GWAS loci identifies rare variants in CARD9, IL23R and RNF186 that are associated with ulcerative colitis. PLoS Genet. 2013;9:e1003723.CrossRefGoogle Scholar
  35. 35.
    Iliev ID, Funari VA, Taylor KD, et al. Interactions between commensal fungi and the C-type lectin receptor Dectin-1 influence colitis. Science. 2012;336:1314–7.CrossRefGoogle Scholar
  36. 36.
    Tang C, Kamiya T, Liu Y, et al. Inhibition of dectin-1 signaling ameliorates colitis by inducing lactobacillus-mediated regulatory T cell expansion in the intestine. Cell Host Microbe. 2015;18:183–97.CrossRefGoogle Scholar
  37. 37.
    Miyoshi J, Leone V, Nobutani K et al (2018) Minimizing confounders and increasing data quality in murine models for studies of the gut microbiome. Peer J. 6:e5166CrossRefGoogle Scholar
  38. 38.
    Qiu X, Zhang F, Yang X, et al. Changes in the composition of intestinal fungi and their role in mice with dextran sulfate sodium-induced colitis. Sci Rep. 2015;5:10416.CrossRefGoogle Scholar
  39. 39.
    Wheeler ML, Limon JJ, Bar AS, et al. Immunological Consequences of Intestinal Fungal Dysbiosis. Cell Host Microbe. 2016;19:865–73.CrossRefGoogle Scholar
  40. 40.
    Ott SJ, Kuhbacher T, Musfeldt M, et al. Fungi and inflammatory bowel diseases: Alterations of composition and diversity. Scand J Gastroenterol. 2008;43:831–41.CrossRefGoogle Scholar
  41. 41.
    Hoarau G, Mukherjee PK, Gower-Rousseau C, et al. Bacteriome and mycobiome interactions underscore microbial dysbiosis in familial Crohn’s disease. MBio. 2016;7:e01250-16.CrossRefGoogle Scholar
  42. 42.
    Chehoud C, Albenberg LG, Judge C, et al. Fungal signature in the gut microbiota of pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis. 2015;21:1948–56.CrossRefGoogle Scholar
  43. 43.
    El Mouzan M, Wang F, Al Mofarreh M, et al. Fungal microbiota profile in newly diagnosed treatment-naive children with Crohn’s disease. J Crohns Colitis. 2017;11:586–92.PubMedGoogle Scholar
  44. 44.
    Lewis JD, Chen EZ, Baldassano RN, et al. Inflammation, antibiotics, and diet as environmental stressors of the gut microbiome in pediatric Crohn’s disease. Cell Host Microbe. 2015;18:489–500.CrossRefGoogle Scholar
  45. 45.
    Duricova D, Burisch J, Jess T, et al. Age-related differences in presentation and course of inflammatory bowel disease: an update on the population-based literature. J Crohns Clitis. 2014;8:1351–61.CrossRefGoogle Scholar
  46. 46.
    Qiu X, Ma J, Jiao C, et al. Alterations in the mucosa-associated fungal microbiota in patients with ulcerative colitis. Oncotarget. 2017;8:107577–88.PubMedPubMedCentralGoogle Scholar
  47. 47.
    Francino MP. Early development of the gut microbiota and immune health. Pathogens. 2014;3:769–90.CrossRefGoogle Scholar
  48. 48.
    Miyoshi J, Bobe AM, Miyoshi S, et al. Peripartum antibiotics promote gut dysbiosis, loss of immune tolerance, and inflammatory bowel disease in genetically prone offspring. Cell Rep. 2017;20:491–504.CrossRefGoogle Scholar
  49. 49.
    Standaert-Vitse A, Jouault T, Vandewalle P, et al. Candida albicans is an immunogen for anti-Saccharomyces cerevisiae antibody markers of Crohn’s disease. Gastroenterology. 2006;130:1764–75.CrossRefGoogle Scholar
  50. 50.
    Standaert-Vitse A, Sendid B, Joossens M, et al. Candida albicans colonization and ASCA in familial Crohn’s disease. Am J Gastroenterol. 2009;104:1745–53.CrossRefGoogle Scholar
  51. 51.
    Quinton JF, Sendid B, Reumaux D, et al. Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut. 1998;42:788–91.CrossRefGoogle Scholar
  52. 52.
    Ruemmele FM, Targan SR, Levy G, et al. Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease. Gastroenterology. 1998;115:822–9.CrossRefGoogle Scholar
  53. 53.
    Peeters M, Joossens S, Vermeire S, et al. Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease. Am J Gastroenterol. 2001;96:730–4.CrossRefGoogle Scholar
  54. 54.
    Forcione DG, Rosen MJ, Kisiel JB, et al. Anti-Saccharomyces cerevisiae antibody (ASCA) positivity is associated with increased risk for early surgery in Crohn’s disease. Gut. 2004;53:1117–22.CrossRefGoogle Scholar
  55. 55.
    Dubinsky MC, Lin YC, Dutridge D, et al. Serum immune responses predict rapid disease progression among children with Crohn’s disease: immune responses predict disease progression. Am J Gastroenterol. 2006;101:360–7.CrossRefGoogle Scholar
  56. 56.
    Tang V, Valin C, Momam R, et al. Assessment of fecal ASCA measurement as a biomarker of crohn disease in pediatric patients. J Pediatr Gastroenterol Nutr. 2017;64:248–53.CrossRefGoogle Scholar
  57. 57.
    Israeli E, Grotto I, Gilburd B, et al. Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease. Gut. 2005;54:1232–6.CrossRefGoogle Scholar
  58. 58.
    Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group. N Engl J Med. 1997;337:1029–35.CrossRefGoogle Scholar
  59. 59.
    Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med. 1999;340:1398–405.CrossRefGoogle Scholar
  60. 60.
    Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359:1541–9.CrossRefGoogle Scholar
  61. 61.
    Sandborn WJ, Hanauer S, Loftus EV, et al. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn’s disease. Am J Gastroenterol. 2004;99:1984–9.CrossRefGoogle Scholar
  62. 62.
    Papadakis KA, Shaye OA, Vasiliauskas EA, et al. Safety and efficacy of adalimumab (D2E7) in Crohn’s disease patients with an attenuated response to infliximab. Am J Gastroenterol. 2005;100:75–9.CrossRefGoogle Scholar
  63. 63.
    Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology. 2006;130:323–33.CrossRefGoogle Scholar
  64. 64.
    Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology. 2007;132:52–65.CrossRefGoogle Scholar
  65. 65.
    Schreiber S, Rutgeerts P, Fedorak RN, et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn’s disease. Gastroenterology. 2005;129:807–18.CrossRefGoogle Scholar
  66. 66.
    Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn’s disease. N Engl J Med. 2007;357:239–50.CrossRefGoogle Scholar
  67. 67.
    Sandborn WJ, Feagan BG, Fedorak RN, et al. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn’s disease. Gastroenterology. 2008;135:1130–41.CrossRefGoogle Scholar
  68. 68.
    Sandborn WJ, Gasink C, Gao LL, et al. Ustekinumab induction and maintenance therapy in refractory Crohn’s disease. N Engl J Med. 2012;367:1519–28.CrossRefGoogle Scholar
  69. 69.
    Whibley N, Jaycox JR, Reid D, et al. Delinking CARD9 and IL-17: CARD9 Protects against Candida tropicalis Infection through a TNF-alpha-Dependent, IL-17-Independent Mechanism. J Immunol. 2015;195:3781–92.CrossRefGoogle Scholar
  70. 70.
    Maher CO, Dunne K, Comerford R, et al. Candida albicans stimulates IL-23 release by human dendritic cells and downstream IL-17 secretion by Vdelta1 T cells. J Immunol. 2015;194:5953–60.CrossRefGoogle Scholar
  71. 71.
    Ordonez ME, Farraye FA, Di Palma JA. Endemic fungal infections in inflammatory bowel disease associated with anti-TNF antibody therapy. Inflamm Bowel Dis. 2013;19:2490–500.CrossRefGoogle Scholar
  72. 72.
    Ford AC, Peyrin-Biroulet L. Opportunistic infections with anti-tumor necrosis factor-alpha therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials. Am J Gastroenterol. 2013;108:1268–76.CrossRefGoogle Scholar
  73. 73.
    Hueber W, Sands BE, Lewitzky S, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012;61:1693–700.CrossRefGoogle Scholar
  74. 74.
    Kelly CR, Kahn S, Kashyap P, et al. Update on fecal microbiota transplantation 2015: indications, methodologies, mechanisms, and outlook. Gastroenterology. 2015;149:223–37.CrossRefGoogle Scholar
  75. 75.
    Colman RJ, Rubin DT. Fecal microbiota transplantation as therapy for inflammatory bowel disease: a systematic review and meta-analysis. J Crohns Colitis. 2014;8:1569–81.CrossRefGoogle Scholar
  76. 76.
    Suskind DL, Brittnacher MJ, Wahbeh G, et al. Fecal microbial transplant effect on clinical outcomes and fecal microbiome in active Crohn’s disease. Inflamm Bowel Dis. 2015;21:556–63.CrossRefGoogle Scholar
  77. 77.
    Cui B, Feng Q, Wang H, et al. Fecal microbiota transplantation through mid-gut for refractory Crohn’s disease: safety, feasibility, and efficacy trial results. J Gastroenterol Hepatol. 2015;30:51–8.CrossRefGoogle Scholar
  78. 78.
    Paramsothy S, Kamm MA, Kaakoush NO, et al. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Lancet. 2017 Mar 25; 389:1218–1228.CrossRefGoogle Scholar

Copyright information

© Japanese Society of Gastroenterology 2018

Authors and Affiliations

  • Jun Miyoshi
    • 1
  • Mark Anthony Sofia
    • 1
  • Joseph Francis Pierre
    • 2
  1. 1.Section of Gastroenterology, Hepatology, and Nutrition, Department of MedicineThe University of ChicagoChicagoUSA
  2. 2.Department of PediatricsThe University of Tennessee Health Science CenterMemphisUSA

Personalised recommendations